Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex

Immunity

Volumn 13, Issue 4, 2000, Pages 529-538

  Slansky, Jill E ^a   Rattis, Frédérique M ^a   Boyd, Lisa F ^b   Fahmy, Tarek ^a   Jaffee, Elizabeth M ^a   Schneck, Jonathan P ^a   Margulies, David H ^b   Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0033696977     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)00052-2     Document Type: Article

References (60)

1. T-cell-receptor affinity and thymocyte positive selection
2. - complexes
3. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR
4. Phenotypic analysis of antigen-specific T lymphocytes
5. Analogues of CTL epitopes with improved MHC class-I binding elicit anti-melanoma CTL recognizing the wild-type epitope
6. The three-dimensional structure of an H-2L(d)-peptide complex explains the unique interaction of L(d) with beta-2 microglobulin and peptide
7. Dendritic cells and the control of immunity
8. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition
9. Tumor antigens recognized by T cells
10. 2-microglobulin
11. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
12. Mimotopes of cytolytic T lymphocytes in cancer immunotherapy
13. Determinant selection of major histocompatibility complex class I-peptide affinity and is strongly influenced by nondominant anchor residues
14. Functional three-domain single-chain T-cell receptor
15. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2L(sd): Sequence motif, quantitative binding, and molecular modeling of the complex
16. T cell receptor-MHC class I peptide interactions: Affinity, kinetics, and specificity
17. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
18. A soluble divalent class J major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations
19. Ligand recognition by aβ T cell receptors
20. Identification of genes coding for tumor antigens recognized by cytotytic T lymphocytes
21. Heteroclitic immunization induces tumor immunity
22. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
23. The makings of a tumor rejection antigen
24. Naive alloreactive CD8 T cells are activated by purified major histocompatibility complex class I and antigenic peptide
25. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19 specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients
26. A colon tumor model for anticancer agent evaluation
27. The immunodominant major histocompatibility class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
28. Isolation of dendritic cells
29. Murine tumor antigens: Is it worth the search?
30. Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity
31. Measuring interactions of MHC class I molecules using surface plasmon resonance
32. Isolation and fractionation of mononuclear cell populations
33. A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor
34. Soluble, high-affinity dimers of the T-cell receptors and class II major histocompatibility complexes: Biochemical probes for analysis and modulation of immune responses
35. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
36. Three-dimentional strcture of H-2D(d) complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120
37. - transplantation antigen P91A: The mutated exon encodes a peptide recognized with L(d) by cytolytic T cells
38. Binding energetics of T-cell receptors: Correlation with immunological consequences
39. MHC class I/peptide interactions: Binding specificity and kinetics
40. Studying interactions involving the T-cell antigen receptor by surface plasmon resonance
41. The bacterial and mouse mammary tumor virus superantigens; two different families of proteins with the same functions
42. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
43. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
44. Counting antigen-specific CD8 T cells: A re-evaluation of bystander activation during viral infection
45. Anaylsis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors
46. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
47. Therapeutic vaccination of cancer
48. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
49. Improved induction of melanoma-reactive CTL with peptide from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
50. A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes
51. Hurran tumor antigens recognized by T cells
52. - peptide analogs define an alternative anchor that can be utilized by L(d) ligands lacking the consensus P2 anchor
53. Immunologic and the rapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
54. A kinetic basis for T cell receptor repertoire selection during an immune response
55. Monitoring antigen-specific T cells using MHC-Ig dimers
56. 2-microglobulin
57. T-lymphocyte response to cytochrome c
58. Stuctural basis of 2C TCR allorecognition of H-2Ld peptide complexes
59. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues
60. b molecule containing a signal viral peptide: Implications for peptide and T-cell receptor recognition